Dr. Glenn serves in a dual role within OmniSeq as SVP of Laboratory Operations and Research Development and Assistant Laboratory Director. Dr. Glenn has overall responsibility of laboratory operations including R&D and clinical services, and performs sign-out of NGS panel testing.
Dr. Glenn is responsible for providing direction in all technology-related issues in support of developing and commercializing OmniSeq’s transformative genomic analysis tools. He participates in strategic planning to align research and product development opportunities with the Company’s objectives.
Dr. Glenn serves on the faculty of Roswell Park Comprehensive Cancer Center in the Molecular and Cellular Biology department and as the Director of Roswell Park’s Genomics Shared Resource (GSR). In those roles, Dr. Glenn interacts with investigators and other core resources to help develop projects utilizing advanced technologies in the ever-growing field of genomics, with a focus of translating cutting-edge technologies into clinical testing modalities. Within the department of Molecular and Cellular Biology, Dr. Glenn focuses on the use of Next Generation Sequencing (NGS) applications in conjunction with mouse modelling for understanding the genetic landscape that drives metastatic disease.
Dr. Glenn received a Bachelor’s of Science in Biology from the State University of New York at Buffalo where he studied the RIP function in Neurospora crassa which is a duplication and mutation event localized to the premeiotic cells of the life cycle. He earned a Master’s of Science from the University at Buffalo focusing on transcriptional regulation of genes responsible for vascular development, and received a PhD in Molecular and Cellular Biology from the Roswell Park Comprehensive Cancer Center, a division of the University of Buffalo. During his PhD studies, Dr. Glenn developed a mouse model that mimics human metastatic pancreatic neuroendocrine carcinoma– a powerful tool for studying the cooperating mutations responsible for the evolution of metastatic disease including the identification and the role circulating tumor cells play in the progression of this process.